Tocilizumab, a recombinant anti-human IL-6 receptor (IL-6R) monoclonal antibody, can block IL-6 signaling transduction and its mediated inflammatory response 7, 8, and thus has attracted much attention on its therapeutic effects in COVID-19 patients 9. Here, IL6 is linked to COVID-19.